Evidence map›Paper›PMID 32045546›Full record

ArticleJCO global oncology2020

Effectiveness of Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Real-Life Setting: One Decade of Experience Under National Treatment Coverage Regulations.

Natalia Camejo, Cecilia Castillo, Rafael Alonso, Fernando Correa, Emiliano Rivero, Camila Mezquita, Agustin Rosich, Fiamma Dellacasa, Luciana Silveira, Lucía Delgado

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO global oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Natalia CamejoDepartment of Clinical Oncology, School of Medicine, University of Uruguay, Montevideo, Uruguay.
Cecilia CastilloDepartment of Clinical Oncology, School of Medicine, University of Uruguay, Montevideo, Uruguay.
Rafael AlonsoDepartment of Quantitative Methods, School of Medicine, University of Uruguay, Montevideo, Uruguay.
Fernando CorreaFondo Nacional de Recursos, Montevideo, Uruguay.
Emiliano RiveroSchool of Medicine, University of Uruguay, Montevideo, Uruguay.
Camila MezquitaSchool of Medicine, University of Uruguay, Montevideo, Uruguay.
Agustin RosichSchool of Medicine, University of Uruguay, Montevideo, Uruguay.
Fiamma DellacasaSchool of Medicine, University of Uruguay, Montevideo, Uruguay.
Luciana SilveiraSchool of Medicine, University of Uruguay, Montevideo, Uruguay.
Lucía DelgadoDepartment of Clinical Oncology, School of Medicine, University of Uruguay, Montevideo, Uruguay.
Universidad de Montevideo · UY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTrastuzumab has shown an overall survival (OS) benefit in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), in both the adjuvant and the metastatic setting. We assessed the effectiveness of trastuzumab in patients treated in daily practice according to national treatment coverage protocols and compared our results with those reported by randomized clinical trials. These coverage protocols included patient selection criteria similar to those of those clinical trials and were developed by the Uruguayan National Resource Fund (FNR), the agency that has funded these prescriptions for more than a decade. PATIENTS AND

methodsWe included all patients with HER2-positive BC treated with trastuzumab under FNR coverage approved between January 1, 2006, and December 31, 2016. The source of data was the FNR database, and primary outcome was OS, analyzed through Cox proportional hazards regression analysis.

resultsA total of 1,944 women were included: 1,085 women (55.8%) were postmenopausal and 1,240 (63.7%) had HER2 and hormone receptor-positive BC. Trastuzumab was administered as adjuvant therapy to 1,233 patients (63.5%), of whom 154 also received it as a neoadjuvant treatment. Three hundred nineteen patients (16.4%) received trastuzumab for advanced disease. Five-year OS in the adjuvant setting was 86.4% (95% CI, 84.0% to 88.7%). The median survival of patients with advanced BC was 25.1 months (95% CI, 10.1 to 42.5 months).

conclusionOur survival results are not inferior to those reported in clinical trials, in both adjuvant and advanced settings. Importantly, these results support the relevance and the feasibility of treating patients in routine practice, following coverage protocols based on patient selection criteria and methods supported by positive clinical trials. In addition, these results favor quality and appropriate access to BC treatment in our country.

Indexed as

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesFemaleHumansTrastuzumabERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesTrastuzumab

Identifiers

PMID32045546
PMCPMC7051800
OpenAlexW3005604038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.